MULTIMODALITY TREATMENT OF LOCALLY ADVANCED PANCREATIC-CANCER

被引：9

作者：

WAGENER, DJT ^{[1
]}

DEMULDER, PHM ^{[1
]}

WILS, JA ^{[1
]}

机构：

[1] LAURENTIUS HOSP,DEPT ONCOL,ROERMOND,NETHERLANDS

来源：

ANNALS OF ONCOLOGY | 1994年 / 5卷

关键词：

PANCREATIC CANCER; CHEMOTHERAPY; IRRADIATION; COMBINED MODALITY TREATMENT;

D O I：

10.1093/annonc/5.suppl_3.S81

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: The prognosis of locally advanced pancreatic cancer is poor (median survival 3-5 months). In view of the localized character of this disease several groups have explored the value of combined modality treatment. The conditions are that a good local treatment and an effective systemic treatment are available. Patients and methods: The results of irradiation and of chemotherapy in advanced disease are reviewed. Results: An overview of combined modality treatment has been given. Conclusions: Results of combined modality treatment are superior to irradiation alone or to symptomatic treatment.

引用

页码：S81 / S86

页数：6

共 57 条

[1] IFOSFAMIDE AND MESNA - MARGINALLY ACTIVE IN PATIENTS WITH ADVANCED-CARCINOMA OF THE PANCREAS [J].

AJANI, JA ;

ABBRUZZESE, JL ;

GOUDEAU, P ;

FAINTUCH, JS ;

YEOMANS, AC ;

BOMAN, BM ;

NICAISE, C ;

LEVIN, B .

JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (11) :1703-1707

[2]

ARBUCK SG, 1990, INT J PANCREATOL, V7, P209

[3]

BERNARD S, 1986, Proceedings American Society of Clinical Oncology Annual Meeting, V5, P84

[4]

BILLINGSLEY JS, 1958, MAYO CLIN P STAFF M, V33, P426

[5]

BRUHL P, 1979, INT J CLIN PHARM TH, V14, P29

[6]

BUKOWSKI RM, 1983, CANCER, V52, P1577, DOI 10.1002/1097-0142(19831101)52:9<1577::AID-CNCR2820520906>3.0.CO

[7]

2-8

[8] SURVIVAL IN 1001 PATIENTS WITH CARCINOMA OF THE PANCREAS [J].

CONNOLLY, MM ;

DAWSON, PJ ;

MICHELASSI, F ;

MOOSSA, AR ;

LOWENSTEIN, F .

ANNALS OF SURGERY, 1987, 206 (03) :366-373

[9]

Cubilla A, 1978, PATHOL ANNU, V1, P241

[10]

Cubilla AL, 1984, ATLAS TUMOR PATHOLOG

← 1 2 3 4 5 6 →